Why Most Supplement Claims Won’t Survive FDA Scrutiny

That freedom is valuable.

It is also easy to misunderstand.

A company may be able to place a claim such as “supports immune health” or “promotes digestive balance” on a product without first submitting the supporting studies to FDA. But if that claim is later examined, the company still needs to be able to show why the science supports what it told consumers.

FDA requires manufacturers making structure/function and related claims under section 403(r)(6) to have substantiation that those statements are truthful and not misleading. FDA's own guidance recommends considering the meaning of the claim, how closely the evidence relates to it, the quality of the evidence, and the totality of the scientific evidence.

The absence of pre-market FDA approval does not mean the absence of scientific accountability.

And that is where many supplement claims become vulnerable.

What DSHEA Freedom Actually Means

DSHEA does not require FDA to pre-approve qualifying structure/function claims before a dietary supplement is marketed.

For a qualifying claim, the company must have substantiation that the statement is truthful and not misleading, include the required disclaimer, and notify FDA no later than 30 days after first marketing the product with the claim.

That system places much of the responsibility on the company.

FDA does not necessarily examine your clinical studies before the claim reaches consumers.

You are expected to have already done the scientific work.

This creates a critical difference between:

“FDA did not stop us from making the claim.”

and:

“The scientific evidence can defend the claim if someone examines it.”

Those are not the same thing.

Why Claims That Look Fine Can Become Difficult to Defend

The weakness is often invisible on the label.

A company may have published studies. The ingredient may have a substantial research history. The supplier may provide a scientific dossier. The claim itself may use familiar structure/function language.

Yet scrutiny asks a different set of questions.

What does the claim actually communicate?

What was studied?

Was the ingredient in the study the same as the one being sold?

Was the dose comparable?

Who participated in the trial?

What outcome actually changed?

Was the effect meaningful?

Does the formulation matter?

And what does the rest of the scientific evidence show?

FDA specifically recommends examining the relationship between the evidence and the claim rather than merely establishing that research exists. It also emphasizes the quality and totality of the evidence.

FTC takes the same problem into advertising. Objective health claims must be adequately substantiated before dissemination, and the evidence must support both the express and implied messages consumers are likely to take from the advertisement.

This means that a claim can sound perfectly ordinary and still have a substantial scientific weakness behind it.

The Evidence Can Fail in More Than One Place

Consider a supplement marketed with a straightforward benefit claim.

The company has a clinical study, but the study used a substantially higher dose.

Or the trial tested a chemically different extract.

Or the participants had a diagnosed condition while the product is marketed to healthy adults.

Or the researchers measured a laboratory biomarker while the advertising promises a noticeable improvement in how consumers feel or function.

Or one positive study is being highlighted while several other studies produced conflicting findings.

Each situation presents a different scientific problem.

And sometimes more than one occurs at the same time.

The vulnerability is not simply “poor evidence.” It is the gap between what the evidence actually establishes and what the claim asks consumers to believe.

A Probiotic Claim Shows How Quickly the Problem Can Grow

Consider a probiotic supplement claiming to:

“Support digestive health.”

The company cites a published human clinical trial.

That sounds reassuring.

But suppose the trial investigated a different probiotic strain, at a substantially higher CFU dose, in people with a diagnosed gastrointestinal condition.

Now the scientific question changes.

Different strains within the same probiotic species can produce different effects. A result demonstrated for one strain should not simply be assumed to occur with another strain because the species name matches.

Dose also matters.

Population matters.

The measured clinical outcome matters.

And the formulation may matter.

So the presence of a human clinical trial does not settle the substantiation question.

The relevant question is whether that trial can reasonably support the claim for the probiotic product actually being sold.

This is exactly the kind of distinction that can disappear when substantiation consists mainly of collecting favorable papers rather than evaluating what each paper can legitimately support.

Scrutiny Goes Beyond Ingredient and Dose

One of the most important weaknesses in supplement claims occurs even when the correct ingredient and dose were studied.

The problem is the conclusion.

Suppose a randomized trial reports a statistically significant improvement in a biological marker.

The marketing department turns that into:

“Supports optimal metabolic health.”

Those statements are not necessarily equivalent.

The study established a particular change in a measured endpoint. The claim communicates a broader consumer benefit.

The scientific question is whether that broader conclusion is justified.

FTC specifically states that statistically significant results should translate into a benefit that is meaningful to consumers. A statistically significant difference can still be too small to support the benefit suggested by advertising.

This creates another common vulnerability:

A positive study does not automatically support the way the result is marketed.

One Good Study May Not Be the Whole Story

Claim substantiation also cannot be reduced to finding the strongest favorable paper.

FDA recommends evaluating the totality of the evidence. Conflicting or inconsistent findings can materially change whether a claim is adequately supported.

FTC likewise evaluates scientific support in light of the entire body of relevant and reliable evidence.

That matters because supplement evidence is rarely perfectly uniform.

A company may find:

one strongly positive trial;
two studies showing smaller effects;
one trial showing no significant benefit;
different outcomes at different doses; or
results that appear only in particular populations.

The scientific task is not to choose whichever study produces the best marketing sentence.

It is to determine what conclusion remains defensible after all of the relevant evidence is considered together.

For the Scientific Reader

Under FD&C Act §403(r)(6), manufacturers making structure/function, general well-being, or nutrient-deficiency claims must possess substantiation that the statement is truthful and not misleading. FDA recommends assessing four core dimensions: claim meaning, evidence-to-claim relationship, methodological quality, and totality of evidence, and states that its approach is intended to be consistent with FTC's competent and reliable scientific evidence framework. For health-related advertising, FTC generally regards randomized controlled human trials as the most reliable form of efficacy evidence and evaluates study design, sample size, outcome measures, statistical analysis, clinically meaningful effect size, population relevance, consistency with the broader evidence base, and whether the tested ingredient or product can legitimately substantiate the marketed product.

What Happens When the Weakness Is Found

The scientific problem rarely stays confined to a scientific file.

A vulnerable claim can affect:

FDA labeling scrutiny;
FTC advertising enforcement;
retailer compliance and market access;
consumer litigation;
investor or acquirer due diligence;
product positioning;
packaging and marketing already in circulation; and
launch timing when evidence problems are discovered late.

This is why claim substantiation is not simply a regulatory paperwork exercise.

A claim may influence packaging, product strategy, advertising spend, retailer conversations and the commercial value proposition around the product.

If that claim later has to be narrowed, changed or withdrawn because the science cannot support it, the consequences can spread well beyond the wording on the label.

The Time to Find the Weakness Is Before Someone Else Does

Scientific weaknesses are much easier to address while a claim is still being developed.

Before launch, a company may still be able to reconsider the proposed claim, strengthen the evidence base, reconsider a dose or formulation decision, or change how the benefit is communicated.

After scrutiny begins, those same decisions may have to be made under pressure.

The product may already be manufactured.

Packaging may already be printed.

Advertising may already be live.

Retailers may already have the claim in their systems.

Investors or partners may already have received materials built around it.

That changes the cost of the problem considerably.

The most useful question before launch is therefore not:

“Do we have studies?”

It is:

“If this claim were challenged tomorrow, what exactly would the science allow us to defend?”

FSC Scientific Perspective

The claims most likely to become vulnerable under scrutiny are not necessarily the most dramatic ones. They are the claims where the company has mistaken the existence of scientific research for proof of the specific benefit being marketed. A defensible claim requires alignment between what consumers are being told and what the relevant body of evidence can actually establish.

Selected Regulatory Sources

U.S. Food and Drug Administration. Guidance for Industry: Substantiation for Dietary Supplement Claims Made Under Section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act. FDA describes the substantiation requirement and its framework for evaluating claim meaning, relevance, evidence quality and totality of evidence. View FDA guidance
U.S. Food and Drug Administration. Notifications for Structure/Function and Related Claims in Dietary Supplement Labeling. FDA explains the substantiation, disclaimer and notification requirements applicable to qualifying 403(r)(6) claims. View FDA resource
U.S. Food and Drug Administration. Dietary Supplement Labeling Guide: Chapter VI. Claims. FDA summarizes requirements applicable to structure/function claims. View FDA guidance
Federal Trade Commission. Health Products Compliance Guidance. FTC, 2022. The guidance explains substantiation of express and implied health claims, competent and reliable scientific evidence, randomized controlled trials, clinically meaningful effects, ingredient-to-product applicability and totality of evidence. View FTC guidance

Why Most Supplement Claims Won't Survive FDA Scrutiny